Morpheus8 can reach 8mm below the skin surface. That is deep enough to pass through the dermis and into subcutaneous fat — and it is exactly why the device can produce dramatic tightening and contouring results. It is also why Morpheus8 can destroy fat that was never meant to be removed.
On October 15, 2025, the FDA issued a safety communication on radiofrequency microneedling devices, citing reports of burns, scarring, fat loss, disfigurement, and nerve damage — some requiring surgical repair. The warning was not specific to Morpheus8. It covered all RF microneedling devices. But Morpheus8's penetration depth — up to 8mm on the face, up to 7mm on the body with the Morpheus8 Body applicator — makes fat loss a uniquely prominent risk.
This is not an anti-Morpheus8 article. The device has FDA 510(k) clearance (K192695, with subsequent clearances K200947 and K240017) for dermatologic procedures involving coagulation and contraction of soft tissue. In July 2024, it became the first fractional RF microneedling device cleared specifically for soft tissue contraction. Over 2.5 million procedures have been performed worldwide. Used conservatively by experienced providers, it produces meaningful results for skin texture, acne scars, and laxity.
The question this article answers is narrower: where is facial fat vulnerable to unintended loss during Morpheus8 treatment, what operator decisions drive that risk, and what does the FDA safety communication actually change?
How Morpheus8 reaches fat
Morpheus8 delivers bipolar radiofrequency energy through an array of insulated gold-tipped needles. The insulation covers the shaft; RF energy exits only at the exposed tip. This means the thermal effect is concentrated at whatever depth the provider has programmed — 0.5mm, 1mm, 2mm, 3mm, 4mm, or deeper depending on the tip.
The facial skin has layered anatomy:
- Epidermis: 0.05–0.1mm
- Dermis: 1–3mm (varies by location; thinner on the forehead and periorbital area, thicker on the cheeks and jawline)
- Subcutaneous fat: begins at approximately 2–4mm depth in most facial zones, depending on the individual
At 1–2mm depth, the needles are in the dermis. The RF energy heats dermal collagen, causing denaturation (unwinding of the triple helix) and triggering a wound-healing response that produces new collagen over 3–6 months. This is the intended mechanism for skin tightening and texture improvement.
At 3mm and above, the needle tip can reach the hypodermis — the subcutaneous fat layer. If RF energy is delivered at sufficient power at this depth, adipocytes (fat cells) are damaged by thermal injury. Unlike dermal collagen, fat cells do not regenerate. The loss is permanent.
The Morpheus8 24-pin face tip reaches up to 4mm. The Morpheus8 40-pin body tip reaches 7mm. The Morpheus8 Body applicator also reaches 7mm with a broader thermal profile. On the face, the fat-loss zone begins at approximately 2–3mm in most patients, which means even moderate face-tip depths can reach it.
Which facial zones are most vulnerable
Fat loss is not equally risky across the face. Some areas have thin skin with fat close to the surface. Others have denser fat pads that are more forgiving but still vulnerable at deeper settings.
High-risk zones for unintended fat loss:
- Temples. The skin here is thin, and the temporal fat pad is superficial. Fat loss in this area creates a hollow, skeletonized appearance that is difficult to reverse.
- Periorbital area. The skin around the eyes is the thinnest on the face (dermis under 1mm in many patients). Even 1–2mm depth can approach the orbital fat compartments. Periorbital fat loss causes a sunken-eye appearance that ages the face significantly.
- Malar/cheek area. The midface fat compartments provide youthful projection. Lipoatrophy here flattens the midface and creates an angular, drawn look. The FDA's own clinical advisory noted periorbital and malar fat loss as areas of particular concern.
- Forehead. Very little subcutaneous fat separates the dermis from the periosteum. Deep treatment here risks both fat loss and discomfort from periosteal contact.
Moderate-risk zones:
- Jawline and jowls. Some providers intentionally use deeper settings here to reduce submental fat or jowls. When this is the plan, it can produce contouring. When it is not — when the provider is treating for skin tightening but using body-depth settings — the result can be an unnaturally sharp jawline or hollowing.
- Perioral area. Fat loss around the mouth is uncommon but can flatten the lips and deepen the nasolabial folds.
Lower-risk zones:
- Nose. Typically treated at very shallow depths (1mm) for pore refinement. Fat loss is rare here.
- Submental area (under chin). This is one of the few facial zones where fat reduction may be a desired outcome. Providers using Morpheus8 at 3–4mm in the submental area are often intentionally targeting fat. The risk is asymmetry or over-reduction.
The operator decisions that drive risk
Fat loss is not random. It results from specific, controllable operator choices:
Needle depth. This is the single most important variable. Depths of 1–2mm are considered safe for facial collagen stimulation while preserving fat in most patients. Depths of 3mm and above on the face begin to approach the hypodermal fat layer, and the risk increases with each additional millimeter. Board-certified physicians who specialize in Morpheus8 generally recommend facial settings not exceed 1–2mm for patients whose primary goal is skin quality rather than contouring.
Energy level (wattage). Morpheus8 energy settings range from 5 to 60+ levels. Higher energy at a given depth produces more thermal damage. The FDA-cleared indication statement for the Morpheus8 applicators includes a specific threshold: at energy levels greater than 62 mJ/pin, use is limited to Fitzpatrick skin types I–IV. This is a regulatory boundary, not a clinical recommendation — it reflects the clearance data on file, not a universal safe maximum.
Pass count and stacking. Multiple passes over the same area, or "stacking" (treating the same zone repeatedly in one session), concentrates thermal energy. The Dermatology Times reporting on the FDA safety communication specifically advised providers to "avoid overlapping passes or high-density stacking, which can contribute to excessive dermal heating and unintended tissue damage."
Burst mode. Morpheus8's Burst feature delivers RF energy to multiple depths in a single pulse (e.g., 2mm, 3mm, and 4mm simultaneously). This is efficient — it treats multiple layers at once — but it also means the fat layer receives energy even if the primary target was the dermis. On the face, burst mode at deeper settings increases the total thermal dose to subcutaneous tissue.
Patient anatomy. Thin-faced patients, patients over 50, and patients with naturally low facial fat are more vulnerable because their fat layer is thinner and closer to the surface. A depth that is safe in a patient with thick skin and robust fat may reach the fat layer in a thin-faced patient.
What the October 2025 FDA safety communication actually said
The FDA's safety communication, issued October 15, 2025, was addressed to patients, caregivers, and healthcare providers. Its key points:
- The FDA is "aware of reports of serious complications" with RF microneedling devices used for dermatologic or aesthetic procedures.
- Reported complications include burns, scarring, fat loss, disfigurement, and nerve damage. Some cases required "surgical repair or medical intervention to treat injuries."
- RF microneedling devices are Class II medical devices cleared through the 510(k) process.
- The FDA is "working with manufacturers of these devices to evaluate the issue and identify mitigation strategies."
- The agency emphasized that RF microneedling is a medical procedure, not a cosmetic treatment, and should not be performed with at-home devices.
- Providers should report adverse events to the FDA through the MedWatch system.
What the communication did not do:
- It did not ban any device.
- It did not name Morpheus8 or any specific platform.
- It did not specify how many adverse event reports triggered the warning.
- It did not establish new depth or energy limits.
Dermatology Times reported that the advisory specifically noted lipoatrophy in the "periorbital and malar regions" as particularly concerning, and recommended that providers "carefully assess treatment depth and energy settings, particularly when treating thin-skinned or bony areas."
The American Academy of Dermatology and multiple board-certified dermatologists responded that serious complications are rare when RF microneedling is performed by experienced, trained providers in appropriate medical settings — and that the complications the FDA described are overwhelmingly associated with improper technique, excessive settings, or non-medical environments.
Who is most vulnerable to fat loss
Thin-faced patients. Anyone with naturally low facial fat, prominent bone structure, or a face that has already lost volume with aging. For these patients, any additional fat loss is immediately visible and difficult to correct. Filler can replace volume but does not replicate the natural fat architecture.
Patients over 50. Facial fat volume decreases with age. Older patients have less margin — the fat layer is thinner, and the visual impact of losing even a small amount is greater. The FDA safety communication did not set age thresholds, but clinical experts generally recommend more conservative settings for older patients.
Patients with prior filler. RF-induced heat may have unpredictable effects on previously injected filler material, including hyaluronic acid, calcium hydroxylapatite, and biostimulators. The Dermatology Times advisory recommended exercising "caution in patients with a history of keloid formation, connective tissue disorders, or prior facial filler treatments, where RF-induced heat may have unpredictable effects."
Patients treated at non-medical settings. Med spas, salons, and mobile injection services may use the device without the anatomical training to assess fat compartment depth or the clinical judgment to adjust settings for individual anatomy. The FDA's warning emphasized that RF microneedling is a medical procedure — an implicit rebuke of the casual-spa treatment framing common in consumer marketing.
The SMAS misconception
A persistent misconception in both provider and patient communities is that Morpheus8 at deeper settings can target the superficial musculoaponeurotic system (SMAS) layer — the deep tissue plane that plastic surgeons manipulate during a surgical facelift — and thereby achieve significant lifting without surgery. This idea is anatomically unsupported. The SMAS cannot be effectively treated or tightened using RF microneedling energy alone. When practitioners attempt to use deeper settings to reach the SMAS, the result is not facelift-level tightening — it is fat loss and scarring in the tissue layers the device passes through on the way down. Board-certified plastic surgeons have identified this misconception as one of the drivers of preventable complications.
What patients should ask before Morpheus8
What depth are you planning for my face, and why? If the answer is 3mm or above on any facial zone other than the jawline or submental area, ask whether a shallower setting could achieve the same result with less risk to facial fat.
Do you adjust depth and energy based on my anatomy, or do you use the same protocol for every patient? The correct answer involves assessment of your skin thickness, fat volume, age, and treatment goals — not a one-size-fits-all setting.
How many passes will you do per zone? Multiple passes increase thermal dose. Ask whether the protocol calls for stacking, and if so, whether it is necessary.
What happens if I lose fat I did not want to lose? A provider worth trusting will acknowledge the risk and explain how they minimize it — not dismiss the question.
Will you use burst mode on my face? Burst mode is efficient but treats multiple depths simultaneously, including the fat layer. Ask whether it is appropriate for your goals and anatomy.
Who is performing the treatment, and what is their training? Board-certified dermatologists and plastic surgeons have the deepest anatomical training. Nurse practitioners and physician assistants can be skilled injectors and device operators, but their scope varies by state and their training depth varies by program.
What the evidence does not yet answer
Several questions about Morpheus8 and fat loss remain unresolved in the published literature:
- Exact incidence. The FDA received enough adverse event reports to issue a safety communication, but the agency did not disclose the number. Without incidence data, it is impossible to quantify the risk precisely. The existing literature on RF microneedling complications consists primarily of case reports and small case series, not large prospective studies.
- Whether fat loss is always permanent. Adipocyte destruction is considered permanent in adults — fat cells do not regenerate. But whether sub-lethal thermal injury to fat can cause temporary volume loss that recovers has not been systematically studied.
- Whether newer applicator tips reduce the risk. Morpheus8 Prime (12-pin, 0.5–1mm) is designed for superficial treatment and is less likely to reach fat. Whether the availability of shallower tips has meaningfully reduced fat-loss reports is not known.
- Long-term outcomes. The 2.5 million procedures cited by InMode include treatments over several years, but most were performed before the October 2025 FDA communication. Whether the warning changes practice patterns, and whether that reduces complications, remains to be seen.
Sources
- FDA Safety Communication: Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling. October 15, 2025. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
- InMode System with Morpheus8 Applicators 510(k) Summary. K192695. https://www.accessdata.fda.gov/cdrh_docs/cfdocs/cfPMN/pmn.cfm?ID=K192695
- InMode System with Morpheus8 Applicators (expanded clearance). K200947. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200947.pdf
- InMode System with Morpheus8 90 Applicator 510(k) Premarket Notification. K240017. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K240017
- Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling. InMode press release, July 17, 2024. https://www.prnewswire.com/il/news-releases/morpheus8-secures-first-and-only-fda-clearance-for-soft-tissue-contraction-for-fractional-radiofrequency-microneedling-302198891.html
- FDA Alerts Clinicians to Serious Complications with Radiofrequency Microneedling Devices. Dermatology Times. October 16, 2025. https://www.dermatologytimes.com/view/fda-alerts-clinicians-to-serious-complications-with-radiofrequency-microneedling-devices
- FDA Warns of Serious Complications with Certain RF Microneedling Devices. Plastic Surgery Practice. October 2025. https://plasticsurgerypractice.com/client-objectives/rejuvenation/med-spa/microneedling/fda-warns-serious-complications-with-rf-microneedling-devices/
- FDA Is Investigating RF Microneedling — Here's What That Actually Means. The AEDITION. 2025. https://aedit.com/aedition/the-fda-is-investigating-rf-microneedling-heres-what-that-actually-means
- Is radiofrequency microneedling safe? What you need to know. Healio Dermatology. November 3, 2025. https://www.healio.com/news/dermatology/20251103/qa-fda-warns-of-radiofrequency-microneedling-risks-heres-what-to-know
- FDA Microneedling Devices page. Updated October 15, 2025. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices
